早期中轴型脊柱关节炎患者中三种新肽段抗体的研究
研究通过噬菌体展示库筛选早期中轴型脊柱关节炎(axial SpA)的新自身抗体,在两个独立队列中验证。发现针对3种UH-axSpA肽段的抗体在早期axial SpA患者中阳性率14.2%(22/155),高于慢性腰背痛对照的5%(4/75),特异性95%,阳性似然比2.7,可提高诊断验后概率。
要点
- 3种UH-axSpA肽段抗体在早期axial SpA中阳性率14.2%,对照5%,特异性95%。
- 阳性似然比2.7,高于C反应蛋白(CRP)的似然比。
- 检测该抗体可使慢性腰背痛患者诊断验后概率从79%升至91%。
核心结论
- 针对3种UH-axSpA肽段的抗体可能成为诊断部分axial SpA患者的新工具。
研究设计与样本
- 使用axial SpA互补DNA噬菌体展示库筛选早期axial SpA患者血浆中的新IgG抗体。
- 在UH队列中通过酶联免疫吸附试验检测76例早期axial SpA、75例非特异性慢性腰背痛对照、60例类风湿关节炎和94例健康对照。
- 在鲁汶大学医院(Bio)SPAR队列的174例axial SpA患者(其中79例早期axial SpA)中进一步验证。
主要发现
- 鉴定了9种新UH-axSpA肽段抗体,对应随机形成的肽段和新axial SpA自身抗原双同源盒蛋白4。
- 选择阳性似然比最高的3种UH-axSpA肽段抗体,在UH和(Bio)SPAR队列的早期axial SpA患者中阳性率为14.2%(22/155),慢性腰背痛对照为5%(4/75)。
关键数值与推荐
- 3种UH-axSpA肽段抗体诊断axial SpA的阳性似然比为2.7,特异性为95%。
- 慢性腰背痛患者检测3种UH-axSpA肽段抗体后,诊断axial SpA的验后概率从79%提高至91%。
临床怎么用
- 对于慢性腰背痛患者,检测3种UH-axSpA肽段抗体可能辅助提高早期axial SpA的诊断概率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study was undertaken to identify novel autoantibodies in axial spondyloarthritis (SpA) and determine their diagnostic potential in patients with early axial SpA and controls from 2 independent cohorts. METHODS: An axial SpA complementary DNA phage display library was used to screen for novel IgG antibodies in plasma from patients with early axial SpA. The presence of these antibodies against novel peptides (i.e., peptides identified in an early axial SpA cohort from Hasselt University, designated UH-axSpA) was determined by enzyme-linked immunosorbent assay in 76 patients with early axial SpA, 75 controls with nonspecific chronic low back pain, 60 patients with rheumatoid arthritis, and 94 healthy controls from the UH cohort. Antibody reactivity to these novel peptides was further validated in 174 patients with axial SpA (of whom 79 had early axial SpA) from the University Hospitals Leuven (Bio)SPAR (Spondyloarthritis [Biologics]) cohort. RESULTS: We identified antibodies to 9 novel UH-axSpA peptides, corresponding to randomly formed peptides and to a novel axial SpA autoantigen, double homeobox protein 4. Antibodies to 3 UH-axSpA peptides with the highest positive likelihood ratio (LR) for a diagnosis of axial SpA were present in significantly more patients with early axial SpA from the UH and (Bio)SPAR cohorts (14.2% [22/155]) compared to controls with chronic low back pain (5% [4/75]), resulting in 95% specificity. The positive LR for confirming axial SpA using antibodies to these 3 UH-axSpA peptides was 2.7, which is higher than the LR obtained with the currently used laboratory marker C-reactive protein. Testing for antibodies to these 3 UH-axSpA peptides in patients with chronic low back pain increased the posttest probability of a diagnosis of axial SpA from 79% to 91%. CONCLUSION: Antibodies to 3 UH-axSpA peptides could provide a novel tool in the diagnosis of a subset of axial SpA patients.
引用
- Quaden D, Vandormael P, Ruytinx P, et al. Antibodies Against Three Novel Peptides in Early Axial Spondyloarthritis Patients From Two Independent Cohorts. Arthritis Rheumatol. 2020. PMID: 32638516. doi:10.1002/art.41427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。